AAM
ALXN

Alpine Associates Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Alpine Associates Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,219,200
Closed -$224M – 69
2021
Q2 		$224M Buy
1,219,200
+173,500
+17% +$29.8M 6.15% 4
2021
Q1 		$160M Buy
1,045,700
+557,100
+114% +$86.2M 4.34% 9
2020
Q4 		$76.3M Buy
+488,600
New +$62.8M 3.12% 13
2015
Q3 		– Sell
-143
Closed -$26K – 68
2015
Q2 		$26K Buy
+143
New +$24.7K ﹤0.01% 75

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Alpine Associates Management's ALXN Position: Q3 2021 in Review

Alpine Associates Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,219,200 shares — an estimated $224M sold.

Alpine Associates Management first reported a position in ALXN in Q2 2015 and held it in 4 quarters. The position peaked at $224M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Alpine Associates Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Alpine Associates Management sold 1,219,200 Alexion Pharmaceuticals shares in Q3 2021, an estimated $224M.
  • Alpine Associates Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • Alpine Associates Management's Alexion Pharmaceuticals position peaked at $224M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Alpine Associates Management's 13F filing for Q3 2021, filed 10 Nov 2021.